Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.

Liu, Chen; Lu, Hengyu; Wang, Hongyun; Loo, Alice; Zhang, Xiamei; Yang, Guizhi; Kowal, Colleen; Delach, Scott; Wang, Ye; Goldoni, Silvia; Hastings, William D; Wong, Karrie; Gao, Hui; Meyer, Matthew J; Moody, Susan E; LaMarche, Matthew J; Engelman, Jeffrey A; Williams, Juliet A; Hammerman, Peter S; Abrams, Tinya J; Mohseni, Morvarid; Caponigro, Giordano; Hao, Huai-Xiang

Liu, Chen; Lu, Hengyu; Wang, Hongyun; Loo, Alice; Zhang, Xiamei; Yang, Guizhi; Kowal, Colleen; Delach, Scott; Wang, Ye; Goldoni, Silvia; Hastings, William D; Wong, Karrie; Gao, Hui; Meyer, Matthew J; Moody, Susan E; LaMarche, Matthew J; Engelman, Jeffrey A; Williams, Juliet A; Hammerman, Peter S; Abrams, Tinya J; Mohseni, Morvarid; Caponigro, Giordano; Hao, Huai-Xiang.

Affiliation

Liu C; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Lu H; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Wang H; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Loo A; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Zhang X; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Yang G; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Kowal C; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Delach S; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Wang Y; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Goldoni S; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Hastings WD; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Wong K; Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Gao H; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Meyer MJ; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Moody SE; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
LaMarche MJ; Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Engelman JA; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Williams JA; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Hammerman PS; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Abrams TJ; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Mohseni M; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
Caponigro G; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts. hxhao81@gmail.com giordano.caponigro@novartis.com.
Hao HX; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts. hxhao81@gmail.com giordano.caponigro@novartis.com.

Clin Cancer Res ; 27(1): 342-354, 2021 01 01.

Article in En | MEDLINE | ID: mdl-33046519

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/pharmacology; Immune Checkpoint Inhibitors/pharmacology; Neoplasms/drug therapy; Protein Kinase Inhibitors/pharmacology; Protein Tyrosine Phosphatase, Non-Receptor Type 11/antagonists & inhibitors; Allosteric Regulation/drug effects; Animals; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Cell Line, Tumor; Cyclin-Dependent Kinase 4/antagonists & inhibitors; Cyclin-Dependent Kinase 6/antagonists & inhibitors; Drug Synergism; ErbB Receptors/antagonists & inhibitors; Female; Humans; Immune Checkpoint Inhibitors/therapeutic use; Mice; Mutation; Neoplasms/genetics; Neoplasms/immunology; Neoplasms/pathology; Programmed Cell Death 1 Receptor/antagonists & inhibitors; Protein Kinase Inhibitors/therapeutic use; Proto-Oncogene Proteins B-raf/antagonists & inhibitors; Proto-Oncogene Proteins B-raf/genetics; Proto-Oncogene Proteins p21(ras)/antagonists & inhibitors; Proto-Oncogene Proteins p21(ras)/genetics; Tumor-Associated Macrophages/drug effects; Tumor-Associated Macrophages/immunology; Xenograft Model Antitumor Assays

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Protein Kinase Inhibitors / Protein Tyrosine Phosphatase, Non-Receptor Type 11 / Immune Checkpoint Inhibitors / Neoplasms Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2021 Type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google